Novakand Pharma AB (publ) (LARK) — Capital Reinvestment Ratio
Novakand Pharma AB (publ) (LARK) has a Capital Reinvestment Ratio of 0.01x as of December 2021, meaning it reinvests 0% of its operating cash flow (Skr22.11 Million) in capital expenditures (Skr147.73K). For the full cash flow conversion analysis, see LARK cash flow conversion.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Novakand Pharma AB (publ) Capital Reinvestment Ratio (2018–2021)
This chart tracks Novakand Pharma AB (publ)'s Capital Reinvestment Ratio across 2 annual periods. Check LARK cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Annual Capital Reinvestment Ratio for Novakand Pharma AB (publ) (2018–2021)
Year-by-year Capital Reinvestment Ratio for Novakand Pharma AB (publ) from 2018 to 2021. See working capital to net assets of Novakand Pharma AB (publ) to evaluate short-term liquidity relative to the company's equity base.
| Year | Reinvestment Ratio | Operating CF (SEK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.01x | Skr22.11 Million | Skr147.73K | ▼ -99.6% |
| 2018 | 1.89x | Skr227.60K | Skr430.20K | — |